Table 2. Efficacy results of ICI monotherapy and ICI + anti-VEGF/TKI combination therapy (RECIST 1.1).
| Monotherapy | Combination therapy (ICI + anti-VEGF, TKI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nivolumab (n=371) | Pembrolizumab (n=183) |
Atezolizumab (n=59) |
Atezolizumab + Bevacizumab (n=60) | Atezolizumab + Bevacizumab (n=336) | Atezolizumab + Bevacizumab (n=104) | Pembrolizumab + Lenvatinib (n=100) | Nivolumab + Lenvatinib (n=24) | ||
| (ChekMate-459) (10) | (KEYNOTE 240) (11) | Phase 1b (2) (Arm F) |
Phase 1b (2) (Arm F) |
(IMbrave 150) (1) |
Phase 1b (2) (Arm A) |
(Phase 1b) (12) | (Phase 1b) (13) | ||
| ORR (%) | 15.0 | 18.3 | 17.0 | 20 | 27.0 | 36.0 | 36.0 | 54.2 | |
| PD (%) | 37.0 | 32.4 | 42.0 | 28 | 20.0 | 24.0 | 7.0 | 8.3 | |
| PFS (M) | 3.7 | 3.0 | 3.4 | 5.6 | 6.8 | 7.1 | 8.6 | 7.4 | |
| OS (M) | 16.4 | 13.9 | N/A | N/A | NR | 17.1 | 22.0 | NR | |
ICI, immune checkpoint inhibitor; VEGF, vascular endothelial growth factor; TKI, tyrosine kinase inhibitor; ORR, objective response rate; PD, progressive disease; PFS, progression-free survival; OS, overall survival; NR, not reached; N/A, not available.